Rocket Pharmaceuticals Inc (NASDAQ: RCKT) is a clinical-stage gene therapy company that develops treatments for rare, devastating diseases using adeno-associated virus and lentiviral vector platforms. The company does not generate product revenue from approved therapies as of the 10-K filed 2026-02-26, and funds operations through equity and debt capital raises rather than commercial sales. The filing identifies cardiovascular programs as a development focus alongside other gene therapy product candidates. Rocket maintains cGMP manufacturing capabilities and holds an intellectual property portfolio supporting its pipeline. The company has disclosed risks related to financial condition and capital needs, indicating it operates with ongoing cash consumption. Leadership, founding year, and specific pipeline asset names are not supported by the provided filing excerpts.

Revenue model

No product revenue from approved therapies is supported by the filing excerpts. Operations are funded through capital raises, as indicated by disclosed risks related to financial condition and capital needs (10-K, filed 2026-02-26).

Products and services

Cardiovascular gene therapy programs and additional gene therapy product candidates in development, utilizing adeno-associated virus and lentiviral vector platforms, with in-house cGMP manufacturing capabilities (10-K, filed 2026-02-26).

Value-chain role

Clinical-stage drug developer and manufacturer of gene therapy vectors, operating upstream of commercialization with internal cGMP manufacturing.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: TG Therapeutics Inc CareDx Inc Design Therapeutics Inc Editas Medicine Inc Geron Corp IGM Biosciences, Inc. Kura Oncology Inc Nuvalent, Inc Replimune Group Inc